Scilex Bio, a joint venture involving Scilex Holding Company, announced that its KDS2010 program is currently enrolling patients in a Phase 2 trial for obesity in South Korea, with a U.S. patient cohort to be added in 2025.
The company reported positive topline results from recently completed Phase 1 trials for oral KDS2010, a novel oral tablet. These trials, involving approximately 90 patients, demonstrated a favorable safety profile and tolerability.
KDS2010 is a potent, selective, and reversible Monoamine oxidase B (MAO-B) inhibitor, distinguishing it from existing treatments. Its mechanism of action, involving selective inhibition of astrocytic GABA, is a new therapeutic strategy for obesity, a market projected to reach $150 billion by the early 2030s.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.